Table 2. Neuroactive drugs and analgesics during MV through an oral ET tube.
| EA group | LA group | NA group | |
|---|---|---|---|
| (n = 37) | (n = 50) | (n = 36) | |
| Details of SPM, n (%) | |||
| Trazodone | 29 (78) | 40 (80) | 0 (0) |
| Quetiapine | 9 (24) | 6 (12) | 0 (0) |
| Mianserin | 9 (24) | 14 (28) | 0 (0) |
| Suvorexant | 2 (5.4) | 0 (0) | 0 (0) |
| Continuous IV neuroactive drugs | |||
| Midazolam, n (%) | 15 (41) | 18 (36) | 12 (33) |
| Average daily midazolam dose, mean [IQR], mg/kg/day | 0.13 [0.09–0.29] | 0.25 [0.14–1.04] | 0.23 [0.14–0.59] |
| Dexmedetomidine, n (%) | 10 (27) | 19 (38) | 17 (47) |
| Average daily dexmedetomidine dose, mean [IQR], μg/kg/day | 1.84 [0.76–3.09] | 2.06 [1.03–3.52] | 2.69 [0.73–4.55] |
| EN neuroactive drugs, n (%) | |||
| Ramelteon | 34 (92) | 42 (84) | 25 (69) |
| Yokukansan | 10 (27) | 17 (34) | 10 (28) |
| Benzodiazepines | 0 (0) | 7 (14) | 1 (3) |
| Other neuroactive drugs | 4 (11) | 6 (12) | 2 (6) |
| Analgesics | |||
| Fentanyl, n (%) | 37 (100) | 50 (100) | 36 (100) |
| Average daily fentanyl dose, mean [IQR], μg/kg/day | 11.15 [7.49–12.77] | 10.73 [8.67–13.20] | 9.92 [6.69–12.72] |
| Acetaminophen, n (%) | 26 (70) | 29 (58) | 14 (39) |
| Average daily acetaminophen dose, mean [IQR], mg/kg/day | 18.03 [12.03–25.53] | 12.70 [8.45–22.65] | 10.72 [6.21–25.59] |
MV, mechanical ventilation; ET, endotracheal; SPM, sleep-promoting medication; ICU, intensive care unit; IQR, interquartile range; IV, intravenous; EN, enteral.